The United States is in the midst of a significant pharmacological development in modern medicine, driven by GLP-1 receptor agonists, the drug class behind Ozempic and Wegovy. These medications have shown remarkable effectiveness in reducing obesity, lowering cardiovascular risk, controlling blood sugar, and even improving areas like addiction and dementia, backed by large-scale clinical trials.
However, despite the overwhelming evidence of their benefits, the accessibility of these medications remains a major issue. The people who would benefit most from GLP-1s are often those with limited financial resources, who face significant barriers to accessing these life-changing treatments.
GLP-1s were originally developed to treat Type 2 diabetes, working by mimicking a hormone produced by the gut that signals the brain to reduce appetite, slow digestion, and stabilize blood sugar levels. Their effects have been so significant that the medical community's interest has expanded beyond diabetes management, with early research exploring their potential in addressing conditions like alcohol use disorder, sleep apnea, and Alzheimer's.
The issue with GLP-1s is not whether they work, but rather the pricing structure, insurance system, and policy environment that have consistently prioritized cost over accessibility. Wegovy, the FDA-approved version for weight management, costs around $1,300 per month without insurance coverage, while Ozempic, approved for Type 2 diabetes, runs at a similar price point.
The price of GLP-1s has increased significantly, with list prices reaching $1,400, creating a market three times larger than cancer spending. However, the actual price a patient pays can vary greatly, depending on their insurance coverage and access to the medication. With commercial insurance that covers obesity, costs can fall to around $25 a month, while the Wegovy pill is available directly through NovoCare at $149 per month.
The coverage gap for GLP-1s is not accidental. It reflects a broader issue with the US healthcare system, where the people who need the most support are often positioned with the least resources to receive it. Obesity disproportionately affects lower-income populations and communities of color, who are more likely to be uninsured or underinsured.
The recent launch of the Medicare GLP-1 Bridge program offers a glimmer of hope, providing eligible beneficiaries with access to Wegovy, Zepbound, and Foundayo for obesity at a flat $50 monthly copay. However, this program is limited, expiring in December 2027, and does not address the broader coverage gap.
To truly move the needle, policy action is required on multiple fronts. The Treat and Reduce Obesity Act, which would permanently lift Medicare's statutory ban on obesity drug coverage, has bipartisan support but has stalled over cost concerns. Medicaid coverage of GLP-1s for obesity needs to be made mandatory at the federal level, and federal drug price negotiation needs to be extended aggressively to this drug class.
The science is clear: GLP-1s have the potential to revolutionize the treatment of obesity and related conditions. What is missing is the political will to match access to what the medicine can actually do.
